Reading view
Beyond Monolithic Architectures: A Multi-Agent Search and Knowledge Optimization Framework for Agentic Search
Balancing Usability and Compliance in AI Smart Devices: A Privacy-by-Design Audit of Google Home, Alexa, and Siri
Fast Mining and Dynamic Time-to-Event Prediction over Multi-sensor Data Streams
Smart IoT-Based Wearable Device for Detection and Monitoring of Common Cow Diseases Using a Novel Machine Learning Technique
Atlas 2 -- Foundation models for clinical deployment
A Framework for Responsible AI Systems: Building Societal Trust through Domain Definition, Trustworthy AI Design, Auditability, Accountability, and Governance
SciClaims: An End-to-End Generative System for Biomedical Claim Analysis
Multi-Modal AI for Remote Patient Monitoring in Cancer Care
Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study
Intervention in Health Misinformation Using Large Language Models for Automated Detection, Thematic Analysis, and Inoculation: Case Study on COVID-19
STAT+: OpenAI invites you to upload medical records to ChatGPT
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Millions of people, including me and possibly you, are already asking ChatGPT questions about health. Still others are dumping otherwise inscrutable medical records downloaded from patient portals into the generative AI bot, hoping to glean new insights.
Now, OpenAI will encourage this behavior with a new health specific tab in the service that the company says has better security and privacy protections so users feel safe pouring sensitive medical data into the bot. In addition to uploading files, users can hook up data from products like Apple Health and Weight Watchers or obtain medical records from providers through b.well’s network. OpenAI promises that it won’t train its models on the data you put into ChatGPT Health. (Reminder: Data that you upload to a consumer service is not covered by HIPAA.)
Continue to STAT+ to read the full story…


© Adobe
National Institutes of Health–Funded Artificial Intelligence and Machine Learning Research, 2019‐2023: Cross-Sectional Study
A Web-Based Cancer Prevention Intervention for Rural Emerging Adults: Mixed Methods Development and Pilot-Testing Study
A Proposed Paradigm for Imputing Missing Multi-Sensor Data in the Healthcare Domain
Clinical Data Goes MEDS? Let's OWL make sense of it
An autonomous agentic workflow for clinical detection of cognitive concerns using large language models
npj Digital Medicine, Published online: 07 January 2026; doi:10.1038/s41746-025-02324-4
An autonomous agentic workflow for clinical detection of cognitive concerns using large language modelsThe Path Ahead for Agentic AI: Challenges and Opportunities
Organoids in translation: a bench-to-bedside framework for pancreatic cancer precision medicine
J Transl Med. 2026 Jan 6. doi: 10.1186/s12967-025-07596-8. Online ahead of print.
ABSTRACT
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a 5-year survival rate of < 13%. Standard treatments such as FOLFIRINOX or gemcitabine/nab-paclitaxel yield modest response rates, underscoring the urgent need for precision oncology approaches. Patient-derived organoids (PDOs) preserve the genomic, phenotypic, and histopathological features of the source tumor and offer a promising platform for drug screening, biomarker development, and personalized therapy. However, a systematic evaluation of their translational capacities is lacking.
METHODS: A systematic review was conducted according to the PRISMA 2020 guidelines (PROSPERO registration pending) using PubMed, EMBASE, and Cochrane CENTRAL (December 10, 2024) to identify English-language PDAC PDO studies that incorporated therapeutic testing. Ninety-five studies met the inclusion criteria. Data extraction captured >75 variables per study, including spanning culture methodology, therapeutic profiling, biomarker integration, and clinical correlation. A 13-domain weighted Translatability Scoring Framework adapted from Wehling et al. assessed predictive validity, biomarker strength, pharmacogenetics, and clinical trial alignment. Scores ranged from 0 to 5 and were categorized as good (>4.0), moderate (3.0-4.0), or low (<3.0) translational potential.
RESULTS: Of the 95 studies, 70.5% have been published since 2021, reflecting the rapid growth in this field. The mean PDO generation success rate was 89.7%, with the primary tumor tissue being the predominant source (48.4%). Only 24.8% were directly linked to clinical trials and 5.3% incorporated multi-omic profiling. The median translatability score was 3.13 (range, 1.72-4.59): 45.3% of the studies had low translatability, 50.5% moderate, and only 4.2% had good translational potential. High-scoring studies consistently combine multi-omic biomarker platforms, in vivo validation, clinical outcome correlation, and prospective trial integration. Conversely, the weakest domains were pharmacogenetics, endpoint strategies, and biomarker validation, limiting their overall clinical relevance.
CONCLUSIONS: PDOs have demonstrated strong feasibility and in vitro clinical correlation in PDAC; however, their clinical translation remains constrained by limited multi-omic integration, absence of pharmacogenomic modeling, and sparse clinical trial embedding. Standardization of protocols, adoption of harmonized and clinically relevant endpoints, and systematic incorporation of biomarker-driven co-clinical trial frameworks are urgently needed to transition PDOs from promising experimental surrogates to validating precision oncology tools capable of informing therapeutic decision-making in PDAC.
PMID:41495743 | DOI:10.1186/s12967-025-07596-8
STAT+: FDA announces sweeping changes to oversight of wearables, AI-enabled devices
LAS VEGAS — The Food and Drug Administration announced Tuesday that it will ease regulation of digital health products, following through on the Trump administration’s promises to deregulate artificial intelligence and promote its widespread use.
FDA Commissioner Marty Makary indicated that one of the agency’s priorities is fostering an environment that’s good for investors, and that FDA regulation needs to move “at Silicon Valley speed.” He announced the changes during an address to conference attendees at the Consumer Electronics Show.
The agency will soften its approach to the regulation of clinical decision support software, which include AI-enabled products that help doctors navigate diagnoses and treatment options. The agency previously considered products that delivered a single recommendation as FDA-regulated medical devices. Now, those products can enter the market without FDA review as long as they fulfill the agency’s other criteria for escaping regulation.
Continue to STAT+ to read the full story…


© ANDREW CABALLERO-REYNOLDS/AFP via Getty Images